BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical development. Previously, Humphrey was...
BioCentury | Aug 29, 2020
Management Tracks

Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

Jingquan Bi was appointed as a deputy director of the Economic Committee of the Chinese People's Political Consultative Conference. He previously served as head of China’s State Drug Administration (now National Medical Products Administration), but...
BioCentury | Jun 17, 2020
Deals

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

...Ideaya Biosciences Inc. (NASDAQ:IDYA) announced a partnership covering three preclinical programs targeting the biosynthetic enzyme MAT2A...
...clinical and sales milestones for the MAT2A program, along with 50% of profits for the MAT2A...
...Create CRISPR Genomics Center” ). Targets BRCA1 - Breast cancer 1 early onset MAT2A - Methionine adenosyltransferase 2A...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group and previously served...
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch...
BioCentury | May 20, 2019
Distillery Therapeutics

MAT2A identified as a target in solid and liquid cancers

...DISEASE CATEGORY: Cancer INDICATION: Lung; leukemia; lymphoma; solid tumors Cell and mouse studies suggest inhibiting MAT2A...
...with low levels of MAT2A. In a mouse model of lung cancer, a tool compound MAT2A...
...MAT2A inhibitors in patient-derived xenograft (PDX) models of lung cancer. Agios Pharmaceuticals Inc. has the MAT2A...
BioCentury | May 8, 2019
Politics & Policy

Azar backs drug importation as he unveils final TV ad rule

In a press briefing announcing a final rule on disclosure of drug prices in television advertisements, HHS Secretary Alex Azar Wednesday expressed his and President Donald Trump’s support for drug importation. “The president and I...
BioCentury | Apr 10, 2019
Company News

U.S. fraud charges pummel Indivior shares

Indivior fell 75.90p (72%) to 30.05p on Wednesday after the U.S. Department of Justice indicted the company for allegedly defrauding providers and payers to increase prescriptions of its opioid dependence drug Suboxone sublingual film. Wednesday's...
BioCentury | Apr 8, 2019
Politics & Policy

Reps. Jordan, Meadows accuse Cummings of 'partisan' drug pricing investigation

Two House Republicans have accused Rep. Elijah Cummings (D-Md.) of leading a partisan investigation into drug pricing, and implied he could leak biopharmas' sensitive, proprietary information. In letters sent to 12 biopharmas, Reps. Jim Jordan...
BioCentury | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
Items per page:
1 - 10 of 113